Recent Updates
Recently added Catalysts
INDV Neutral Sentiment Score: 60/100

Indivior Announces Q1 2025 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor...

Key Takeaway: Indivior PLC announced its financial results for Q1 2025, ending March 31, 2025. The company focuses on developing treatments for opioid use disorder and aims to provide evidence-based treatment access globally. A webcast detailing the financial results will be hosted by CEO Mark Crossley. Indivior's commitment to OUD treatment is reflected in their expanding portfolio and pipeline of products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior continues to expand its global portfolio of OUD treatments.
  • The company is dedicated to transforming opioid use disorder into a recognized chronic disease.

Full Press Release Details

SLOUGH, United Kingdom and RICHMOND, Va. , April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am ET ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/yn37cxqk Participants may access the presentation telephonically by registering with the following link: https://register-conf.media-server.com/register/BI4482694d7c294502b6a4dedd62e88c5b (Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond , VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What were Indivior's financial results announced?

Indivior PLC announced its financial results for the period ending March 31, 2025.

When is the live webcast presentation scheduled?

The live webcast presentation is on April 24, 2025, at 13:00 BST (8:00 am ET).

What is Indivior focused on treating?

Indivior is dedicated to developing medicines for opioid use disorder (OUD).

How does Indivior aim to change OUD treatment?

Indivior aims to transform OUD into a recognized and treated chronic disease.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, Virginia, United States.

Last updated: Apr 24, 2025